Abstract. Long-term cetuximab treatment can lead to acquired resistance, and tumor progression and/or new lesions often occur. The present report describes a case of lower gingival squamous cell carcinoma with brain metastasis during long-term cetuximab treatment in a 60-year-old man, including findings of an immunohistochemical study. The resected primary tumors, biopsy of the lung metastasis before administration of cetuximab, and brain metastasis specimens mediated by cetuximab were immunohistochemically examined. Histologically, the metastatic brain lesion showed hyperkeratinizing tumor cells with deeply stained irregular nuclei with necrotizing tumor cells, and a decrease in cell density was exhibited in part of the tumor nest. Moreover, the brain lesion was less malignant compared with the primary tumor and metastatic lung lesions. Immunohistochemically, the metastatic brain lesions showed low expression of epidermal growth factor receptor (EGFR) and high expression of N-cadherin compared with the primary tumor and metastatic lung lesions. These results suggest that acquired resistance to cetuximab may be associated with low EGFR expression and increased epithelial-to-mesenchymal transition potential.

Introduction

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline has suggested that platinum-based systemic therapy including cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, is the gold standard treatment and leads to an increase in progression-free survival and overall survival in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (1,2). Other studies have suggested that the addition of cetuximab to weekly paclitaxel is effective for patients who present resistance or are not candidates for platinum-based chemotherapy (3). In contrast, long-term administration can lead to acquired resistance to cetuximab in tumor cells, and tumor progression or metastasis are often experienced. Although several molecular mechanisms, such as Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations and the constitutive activation of EGFR and its downstream pathways, have been reported to be involved in cetuximab resistance (4), histopathological and immunohistochemical changes mediated by cetuximab have not yet been investigated, and the details underlying the mechanisms of resistance remain unclear.

We describe our experience with a case of lower gingival squamous cell carcinoma with isolated brain metastasis during long-term cetuximab treatment, including findings of an immunohistochemical study.

Case report

A 60-year-old man with a history of lumbar compression fracture was referred to the Nagasaki University Hospital with a complaint of pain in the left mandibular gingiva. Consent was provided to publish the present data. He had smoked 30 cigarettes per day for 40 years and also reported an alcohol intake of two glasses of shochu water per day for 30 years. Intraoral examination revealed a 35x30 mm elastic hard mass with a central ulceration involving the left mandibular gingiva, which was immediately evaluated via imaging and incisional biopsy. Contrast-enhanced axial computed tomography (CT) showed a 32x23 mm poorly marginated lesion with bone destruction that extended along the buccal and lingual surfaces of the mandible, but no regional lymph node involvement (Fig. 1). The biopsy specimen exhibited signs of well-differentiated

Correspondence to: Dr Tomofumi Naruse, Department of Clinical Oral Oncology, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8588, Japan
E-mail: naruse12@nagasaki-u.ac.jp

Abbreviations: EGFR, epidermal growth factor receptor; NCCN, National Comprehensive Cancer Network; R/M, recurrent/metastatic; KRAS, Kirsten rat sarcoma viral oncogene homolog; CT, computed tomography; HNSCC, head and neck squamous cell carcinoma; CRT, chemoradiotherapy; DM, distant metastasis; MRI, magnetic resonance imaging; BBB, blood brain barrier; BTB, blood-tumor barrier; EMT, epithelial-to-mesenchymal transition

Key words: oral squamous cell carcinoma, brain metastasis, cetuximab resistance, epidermal growth factor receptor, epithelial-to-mesenchymal transition
squamous cell carcinoma (SCC) invading the submucosal tissue from the mucosal epithelium, and he was diagnosed with SCC of the mandible (T4N0M0 stage IVA). Under general anesthesia, he underwent segmental mandibulectomy, modified radical neck dissection, and reconstruction with fibula osteocutaneous free flaps. However, because unreseetable regional recurrence occurred between the splenius muscle and levator scapulae muscle 2 months after surgery, he underwent high dose platinum-based chemoradiotherapy (CRT) for curative treatment (Fig. 2). Radiotherapy (RT) was performed using a total of 66 Gy. Concomitant RT was administered at 2 Gy/d for 5 d/wk. Chemotherapy consisted of a total of 200 mg cisplatin per square meter of body surface during a course of RT. However, multiple lesions occurred in the lung fields during the CRT. Transbronchial biopsy was performed by the department of respiratory medicine, and metastasis of oral squamous cell carcinoma (OSCC) was pathologically diagnosed (Fig. 3). Because he experienced failure of a platinum-based therapy, cetuximab plus paclitaxel were started. Cetuximab was administered at a dose of 400 mg per square meter of body for the first injection and 250 mg per square meter of body weekly thereafter. Paclitaxel was administered weekly at a dose of 80 mg per square meter of body. After 57 courses were administered, as speech disturbances and decreased cognitive function were apparent, brain enhanced magnetic resonance imaging (MRI) was performed and brain distant metastases (DMs) were detected, in spite of better loco-regional and lung DM control. Palliative surgery against the brain metastases was performed by the department of neurosurgery, and metastasis of OSCC was pathologically diagnosed (Fig. 4). Following surgery, the best supportive care has been provided by another hospital and he subsequently died because of cachexia 2 months after palliative surgery.

Pathological findings revealed that primary tumors showed keratinizing tumor cells that had relatively round or cord-like tumor nests with deeply stained irregular nuclei, and tumor cells infiltrated from the gingival epithelium to the submucosa, surrounding the muscle layer and bone marrow of the mandible. Lung DM lesions showed keratinizing tumor cells that had round tumor nests with irregular nuclei and prominent nucleoli. In contrast, brain DM lesions showed a neoplastic appearance comprising hyperkeratinizing tumor cells with deeply stained irregular nuclei, but necrotizing tumor cells and a decrease in cell density were also seen in part of tumor nest. Taken together, tumor cellularity was lower compared to the primary tumor and lung DM lesion due to the administration of cetuximab (Fig. 5).

Immunohistochemistry was performed using paraffin-embedded sections of resected primary tumors, biopsies lung DM specimens, and brain DM specimens. The following primary antibodies were used: EGFR (D38B1; dilution 1:50; CST, Tokyo, Japan), EGFRv3 (9E05M52; dilution 1:200; Bioss Inc., Woburn, MA, USA), CD44v6 (ab78960; dilution 1:100; Abcam, Cambridge, UK), ABCG2 (ab3380; dilution 1:50; Abcam), E-cadherin (M3612; dilution 1:50; Dako; Agilent Technologies, Inc., Glostrup, Denmark), and N-cadherin (M3618; dilution 1:50; Dako; Agilent Technologies, Inc.). Immunohistochemistry revealed that EGFR was strongly expressed primarily in the cell membrane of tumor cells in the primary tumor and lung DM lesions. Strong expression was especially observed at the invasive front. By contrast, in the brain DM lesions, EGFR was weakly or not expressed in the tumor nests, and a marked difference between the lung and brain lesions was observed. EGFRv3 was weakly or not expressed in the primary tumor, lung DM specimens, and brain DM specimens. CD44v6 was strongly expressed in the primary tumor, lung DM specimens, and brain DM specimens, and no marked difference in these markers was observed between the lung and brain DM (Fig. 6A). ABCG2 was weakly or not expressed in the primary tumor, lung DM specimens, and brain DM specimens; no marked difference was observed. E-cadherin was expressed in the tumor nest, but weakly expressed in the invasion front of the primary tumor. E-cadherin was also expressed in the lung DM specimens, but was not expressed in the brain DM specimens. N-cadherin was not expressed in the primary tumor or lung DM lesions, but it was expressed in the brain DM (Fig. 6B).

Discussion

Although the NCCN Clinical Practice Guideline has suggested that systemic therapy including cetuximab is the gold standard for very advanced HNSCC (1), there are few studies on patients receiving long-term cetuximab treatment. Here, we determined the histological and immunohistochemical responses in a case of isolated brain DM of OSCC with loco-regional and lung control. The incidence of DM in patients with OSCC after standard therapy has recently been reported to range from 3.2 to 9.6% (5-8). Among these reports, the incidence of isolated DM has been reported as 3.2% (7), and the incidence of brain DM has been reported to range from 1.3 to 3.3% (5,7). From these reports, it can be suggested that our case was extremely unusual.

There are several potential reasons for the occurrence of brain DM in our case. Although tumor cellularity was decreased and certain anti-tumor effects of cetuximab were observed, tumor recurrence was detected only in the brain region during systemic therapy in our case, and the blood brain barrier (BBB) was suspected to be a factor of weakening effect. Regarding cetuximab and the BBB, some authors reported that cetuximab molecules (152 kDa and 15 nm) are large relative to the size of the BBB junctions, and may not cross the BBB in conventional systemic therapy (9,10). In addition, the BBB in malignant brain tumors [also referred to as the blood-tumor barrier (BTB)] is abnormal and variably disrupted within the main body of the tumor and nearby tissue, and the BTB may be shielded from the effects of chemotherapy (11). For these reasons, the frequency of brain metastasis may be increased in R/M OSCC during cetuximab treatment. According to the NCCN guideline, fluoro-deoxyglucose- positron emission tomography/CT has been recommended to assess the extent of disease or DM at a minimum of 12 weeks if the patient responds to systemic therapy/RT (1). However, it may not be useful in detecting brain metastasis. Although enhanced MRI may be useful for detecting metastasis, brain and loco-regional metastases may not be examined at the same time, depending on institutional imaging conditions. Therefore, the frequency of brain screening will be controversial. In addition, speech disturbances or decreased cognitive function would be apparent when brain metastasis is suspected, and it is important to avoid missing these symptoms at an early stage.
The effects of long-term administration of cetuximab on brain metastasis were immunohistochemically examined. EGFR expression in the metastatic brain lesions in our patient was remarkably decreased compared with the primary tumor and metastatic lung lesions. Benavente et al reported that, when EGF-stimulated activation of EGFR was inhibited, other signaling molecules, such as protein kinase B, mitogen-activated protein kinase, and phosphorylated signal transducer and activator of transcription 3 were upregulated, as in cetuximab-resistant HNSCC cell lines (12). Moreover, Hatakeyama et al reported that EGFR activation leads to activation of downstream pathways, and that downstream effectors are implicated in resistance to EGFR inhibition (13). In contrast, Kimura et al reported that cetuximab-resistant cell lines exhibited reduced levels of EGFR expression and increased epithelial-to-mesenchymal transition (EMT)-associated genes, indicating the association of treatment responses (14). In the present study, we found that metastatic brain lesions were composed of selectively residual EGFR-low-expressing cells refractory to cetuximab. Our results are in agreement with those in previous reports.

With regard to EMT, Schmitz et al also reported a correlation between upregulation of EMT markers and cetuximab resistance using 20 pre- and post-cetuximab HNSCC biopsy specimens (15). However, as the patient underwent the short-term cetuximab treatment before...
surgery, the relationship between long-term cetuximab treatment and acquired resistance to cetuximab remains unclear. In the present study, E-cadherin was expressed in the lung DM lesions, whereas it was weakly or not expressed in the primary tumor and brain DM lesions. Although it was suspected that primary tumor cells could already have EMT potential, it appears to have been lost in lung DM cells. These results could be attributed to the influence of high-dose CRT. Interestingly, N-cadherin expression in the metastatic brain lesions was increased compared to the primary tumor and metastatic lung lesions, and a cadherin switch profile (low E-cadherin and high N-cadherin expression concurrently), known as a feature of EMT was observed. As it has been reported that cadherin switching from E-cadherin to N-cadherin may play a critical role in development and metastasis of OSCC (16), one of the features of cetuximab resistant cells is suggested.

EGFRv3 is the most common EGFR alteration. This mutation makes the receptor unable to bind its ligand and it therefore signals constitutively. It is co-expressed with wild type EGFR in many cancers, including HNSCC. Wheeler et al reported that activation of the EGFR pathway thorough EGFRv3 led to activation of target genes and subsequent cetuximab resistance (17,18). However, in the present study, there was no difference in EGFRv3 expression between the lung and brain lesions. This result suggested that there is no correlation between acquired resistance to cetuximab and EGFRv3. Moreover, because it was suspected that the occurrence of brain metastasis during systemic therapy was related to cancer stem cells (CSCs), we examined the expressions of CSC markers (CD44v6 and ABCG2) (19). However, we observed no difference in CD44v6 and ABCG2 expression between the lung and brain lesions. However, La Fleur et al reported that CD44high/EGFRlow cells show an EMT phenotype and resistance to cetuximab treatment, and our results are agreement with this finding (20).

In conclusion, the results of this study suggest that acquired resistance to cetuximab is associated with low EGFR

---

**Figure 6.** Representative immunohistochemical features of oral squamous cell carcinoma. (A) Epidermal growth factor receptor expression was decreased in the brain distant metastasis (DM) compared to the primary tumor and lung DM (magnification, x400). (B) E-cadherin expression was decreased and N-cadherin expression was increased between lung and brain DM lesion (magnification, x400).
expression and EMT potential. One limitation of our work is that we examined only one patient, and many biases must exist, including tumor heterogeneity. In addition, because our study examined an R/M OSCC terminal stage patient during long-term cetuximab treatment, the number of tumor sections we could safely collect in a real clinical situation was limited. Therefore, an intergroup study with an increased number of cases is needed.

Conflicts of interest statement

The authors declare that they have no competing interests.

References

11. Black KL and Ningaraj NS: Modulation of brain tumor capil-


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.